Wolverine Store

SOURCE INDEX // 07

References and sources

Every BPC-157 TB-500 claim on this site resolves to a source below — peer-reviewed studies and reviews with PubMed links and DOIs, plus the audited FDA regulatory record.

Read the researchLatest research

How to read this list

These are the BPC-157 TB-500 references cited across the site. Entries 1-16 are peer-reviewed studies and reviews on the two constituents; entries 17-24 are the audited regulatory and anti-doping sources. Every quantitative claim in the body pages maps to a numbered entry here. Constituent findings are single-compound: none of these references reports a controlled study of the combination.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  5. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  6. Vukojevic J, et al. Pharmacokinetic context for BPC-157: the stable gastric pentadecapeptide's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study, as summarized in the audited compound corpus for the BPC-157 + TB-500 blend. ↗
  7. Morris DC, et al. Thymosin beta-4 improves functional neurological outcome in a rat embolic stroke model, with a non-monotonic dose-response (2-18 mg/kg; modeled optimum ~3.75 mg/kg; 18 mg/kg without benefit). Neuroscience. 2010;169(2):674-682. ↗
  8. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in cytoprotection and gastric-ulcer research, including rat dosing in the 400-800 ng/kg range, as consolidated in the BPC-157 review literature. Curr Pharm Des. 2010;16(10):1224-1234. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical, 1 human; no clinical safety data; evidence graded level IV-V; no mention of TB-500 or any combination.) ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. ↗
  12. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  13. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. ↗
  14. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. ↗
  15. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
  16. Human and pharmacokinetic data summary for BPC-157 and TB-500/Thymosin Beta-4, consolidated in the audited Wolverine (BPC-157 + TB-500) compound corpus: three small BPC-157 pilot studies; human "TB-500" data are for full-length Thymosin Beta-4 (Ruff 2010 Phase 1 IV in 40 volunteers; a 2021 first-in-human study in 84 volunteers; topical ophthalmic trials). No controlled combination trial exists. ↗
  17. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (calendar listing BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances being considered for inclusion on the 503A Bulks List). FDA, verified 2026-05-29. ↗
  18. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (PCAC discussion is a step in evaluation, informing FDA rulemaking; being discussed is not a final listing decision). FDA, verified 2026-05-29. ↗
  19. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; effective with the September 29, 2023 list update). FDA, verified 2026-05-29. ↗
  20. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (503A patient-specific compounding vs 503B outsourcing facilities; bulk-substance eligibility via USP/NF monograph, component of an approved drug, or the FDA bulks list). FDA, verified 2026-05-29. ↗
  21. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 vs Category 2: Category 2 substances were identified as raising significant safety risks and are not covered by FDA's enforcement-discretion policy). FDA, verified 2026-05-29. ↗
  22. Audited regulatory-access reference (config/regulatory-access-503a.json): the lawful U.S. compounded-medication pathway — licensed-prescriber evaluation, valid patient-specific prescription, dispensing by a 503A compounding pharmacy or sourcing from a 503B outsourcing facility, with the ingredient-eligibility caveat that FDA-flagged significant-safety-risk substances are not eligible for routine 503A compounding while that status stands. Grounded in FDA sources, verified 2026-05-29. ↗
  23. Audited regulatory-access reference (config/regulatory-access-503a.json): telehealth is a front-end consultation channel for the prescriber-evaluation step, not a separate legal status; it does not expand which substances may be compounded or remove the need for a legitimate clinical evaluation and a valid prescription. Grounded in FDA sources, verified 2026-05-29. ↗
  24. World Anti-Doping Agency. The Prohibited List (BPC-157 under S0 Non-Approved Substances; thymosin beta-4 / TB-500 under prohibited peptide and growth-factor categories), as consolidated in the audited Wolverine compound corpus compliance record. ↗